Heart failure management in the emergency department observation unit

Progress in Cardiovascular Diseases

Volumn 46, Issue 5, 2004, Pages 465-485

  Peacock, W Frank ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; GLYCERYL TRINITRATE; MAGNESIUM; NESIRITIDE; NITROPRUSSIDE SODIUM; POTASSIUM; SPIRONOLACTONE;

AMINO TERMINAL SEQUENCE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CLINICAL EXAMINATION; CLINICAL FEATURE; COHORT ANALYSIS; CONFUSION; CORRELATION ANALYSIS; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIFFERENTIAL DIAGNOSIS; DRUG CONTRAINDICATION; EMERGENCY WARD; GASTROINTESTINAL TOXICITY; HEART BLOCK; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; MORBIDITY; MORTALITY; NEUROTOXICITY; PHYSICAL EXAMINATION; PROGNOSIS; REVIEW; RISK MANAGEMENT; SYSTOLIC BLOOD PRESSURE; THORAX RADIOGRAPHY; VISUAL DISORDER; VITAMIN SUPPLEMENTATION;

EID: 2442685201     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2003.12.004     Document Type: Article

References (107)

1. Packer M., Cohn J.N. Consensus recommendations for the management of chronic heart failure. Am J Cardiol. 83:(2A):1999;1A-38A
2. Massie B.M., Shah N.B. Evolving trends in epidemiologic factors of heart failure Rationale for preventative strategies and comprehensive disease management. Am Heart J. 133:1997;703-712
3. Packer M., Carver J.R., Rodeheffer R.J., et al. Promise Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 325:1991;1468-1475
4. CMS 2001 in-patient discharge data base: MEDPAR, DRG 427
5. Peacock W.F. 4th, Remer E.E., Aponte J., et al. Effective observation unit treatment of decompensated heart failure. Congest Heart Fail. 8:2002;68-73
6. Friesinger G.C. Cardiology Clinics. 1999;Saunders, Philadelphia, PA
7. Rich M.W. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc. 45:1997;968-974
8. Remes J., Miettinen H., Reunanen A., et al. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J. 12:1991;315-321
9. Marantz P.R., Tobin J.N., Wassertheil-Smoller S., et al. The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria. Circulation. 77:1988;607-612
10. Stevenson L.W. The limited availability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 261:1998;884-888
11. Davis A.P., Francis C.M., Love M.P., et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. Br Med J. 312:1996;222
12. Marantz P.R., Kaplan M.C., Alderman M.H. Clinical diagnosis of congestive heart failure in patients with acute dyspnea. Chest. 97:1990;776-781
13. Chakko S., Woska D., Marinez H., et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure Conflicting results may lead to inappropriate care. Am J Med. 90:1991;353-359
14. Kono T., Suwa M., Hanada H., et al. Clinical significance of normal cardiac silhouette in dilated cardiomyopathy - Evaluation based upon echocardiography and magnetic resonance imaging. Jpn Circ J. 56:1992;359-365
15. Ruskin J.A., Gurney J.W., Thorsen M.K., et al. Detection of pleural effusions on supine chest radiographs. AJR Am J Roentgenol. 148:1987;681-683
16. Chait A., Cohen H.E., Meltzer L.E., et al. The bedside chest radiograph in the evaluation of incipient heart failure. Radiology. 105:1972;563-566
17. Butman S.M., Ewy G.A., Standen J.R., et al. Bedside cardiovascular examination in patients with severe chronic heart failure Importance of resting or inducible jugular venous distention. J Am Coll Cardiol. 22:1993;968-974
18. Marantz P.R., Kaplan M.C., Alderman M.H. Clinical diagnosis of congestive heart failure in patients with acute dyspnea. Circulation. 88:1993;107-115
19. Peacock W.F., Kies P., Albert N.M., et al. Bioimpedance monitoring for detecting pulmonary fluid in heart failure Equal to chest radiography? Congest Heart Fail. 6:2000;86-89
20. Dao Q., Krishnaswamy P., Kazanegra R., et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 37:2001;379-385
21. Cowie M.R., Struthers A.D., Wood D.A., et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 350:1997;1349-1353
22. McKee P.A., Castelli W.P., McNamara P.M., et al. The natural history of congestive heart failure The Framingham Study. N Engl J Med. 285:1971;1441-1446
23. Francis C.M., Caruana L., Kearney P., et al. Open access echocardiography in management of heart failure in the community. BMJ. 310:1995;634-636
24. ACC/AHA. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult. [Cited March 18, 2002]. Available from: http://www.acc.org/clinical/guidelines/failure/I_introduction.htm
25. USDHHS. Heart failure Evaluation and care of patients with left-ventricular systolic dysfunction (Clinical Practice Guideline, Number 11, AHCPR publication No. 94-0612). 1994;US Department of Health and Human Services, Washington, DC. June
26. Wheeldon N.M., MacDonald T.M., Flucker C.J., et al. Echocardiography in chronic heart failure in the community. Q J Med. 86:1993;255-261
27. Anonymous. Studies of left ventricular dysfunction (SOLVD) - Rationale, design and methods Two trials that evaluate the effect of enlapril in patients with reduced ejection fraction. Am J Cardiol. 66:1990;315-322
28. Hobbs R.E., Czerska M.D. Congestive heart failure. Current and future strategies to decrease mortality. Postgrad Med. 96:1994;167-172
29. Batsford W.P., Mickleborough L.L., Elefteriades J.A. Ventricular arrhythmias in heart failure. Cardiol Clin. 13:1995;87-91
30. Clemens L.E., Almirez R.G., Baudouin K.A., et al. Pharmacokinetics and biological actions of subcutaneously administered human brain natriuretic peptide. J Pharmacol Exp Ther. 287:1998;67-71
31. Nakao K., Mukoyama M., Hosoda K., et al. Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide. Can J Physiol Pharmacol. 59:1991;1500-1506
32. Mair J., Thomas S., Puschendorf B. Natriuretic peptides in assessment of left-ventricular dysfunction. Scan J Clin Invest. 59:(Suppl 230):1999;132-142
33. Struthers A.D. Ten years of natriuretic peptide research A new dawn for their diagnostic and therapeutic use? BMJ. 308:1994;1615-1619
34. Ghali J.K., Kadakia S., Cooper R.S., et al. Bedside diagnosis of preserved versus impaired left ventricular systolic function in heart failure. Am J Cardiol. 67:1991;1002-1006
35. Stevenson W.G., Stevenson L.W., Middlekauff H.R., et al. Sudden death prevention in patients with advanced ventricular dysfunction. Circulation. 88:1993;2953-2961
36. Stevens T.L., Rasmussen T.E., Wei C.M., et al. Renal role of the endogenous natriuretic peptide system in acute congestive heart failure. J Card Fail. 2:1996;119-125
37. Peacock W.F., Albert N.M., Kies P., et al. Emergency department observation unit heart failure protocol decreases adverse outcome rates. J Card Fail. 5:(Suppl 1):1999;77
38. Maeda K., Tsutamoto T., Wada A., et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 135:1998;825-832
39. Yamamoto K., Burnett J.C., Jougasaki M., et al. Superiority of brain natriuretic peptide as a humoral marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 28:1996;988-994
40. Omland T., Aakvaag A., Bonarjee V., et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction Comparison with plasma atrial natriuretic peptide and n-terminal proatrial natriuretic peptide. Circulation. 93:1996;1963-1969
41. Kazanegra R., Cheng V., Garcia A., et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure A pilot study. J Card Fail. 7:2001;21-29
42. Jensen K.T., Carstens J., Ivarsen P., et al. A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases. Scand J Clin Lab Invest. 57:1997;529-540
43. Mukoyama M. Augmented secretion of BNP in MI. Biochem Biophys Res Commun. 180:1991;431-436
44. Kohse K.P. Differential regulation of brain and atrial natriuretic peptides in hemodialysis patients. Clin Nephrol. 40:1993;83-90
45. Buckley M.G., Markandu N.D., Miller M.A., et al. Plasma concentrations and comparisons of brain and atrial natriuretic peptide in normal subjects and in patients with essential hypertension. J Hum Hypertens. 3:1993;345-350
46. Wallen T., Landahl T., Herner T., et al. Brain natriuretic peptide in an elderly population. J Intern Med. 242:1997;307-311
47. Sayama H., Nakamura Y., Saito N., et al. Relationship between left ventricular geometry and brain natriuretic peptide levels in elderly subjects. Gerontology. 46:2000;71-77
48. Lernfelt B. Aging and left ventricular function in elderly healthy people. Am J Cardiol. 68:1991;547-549
49. Nagaya N., Nishikimi T., Uematsu M., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 102:2000;865-870
50. Niinuma H., Nakamura M., Hirarnori K. Plasma B-type natriuretic peptide measurement in a multiphasic health screening program. Cardiology. 90:1998;89-94
51. Davis M., Espiner E., Richards G., et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet. 343:1994;440-444
52. McDonagh T.A., Robb S.D., Morton J.J., et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 351:1998;9-13
53. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 347:2002;161-167
54. Bettencourt P., Ferreira A., Dias P., et al. Evaluation of brain natriuretic peptide in the diagnosis of heart failure. Cardiology. 93:2000;19-25
55. Fujimora M., Yasumura Y., Ishida Y., et al. Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy. J Card Fail. 6:2000;3-10
56. Nishikimi T., Matsuoka H., Ishikawa K., et al. Antihypertensive therapy reduces increased plasma levels of adrenomedullin and brain natriuretic peptide concomitant with regression of left ventricular hypertrophy in a patient with malignant hypertension. Hypertens Res. 19:1996;97-101
57. Cheng V., Kazanagra R., Garcia A., et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure A pilot study. J Am Coll Cardiol. 37:2001;386-391
58. Selvais P., Donckier J., Laloux R., et al. Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure Influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation. Eur J Clin Invest. 28:1998;636-642
59. Tsutamoto T., Wada A., Maeda K., et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Eur Heart J. 20:1999;1799-1807
60. Yu C.M., Sanderson J.E. Plasma brain natriuretic peptide - An independent predictor of cardiovascular mortality in acute heart failure. Eur J Heart Fail. 1:1999;59-65
61. Harrison A., Morrison L.K., Krishnaswamy P., et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med. 39:2002;131-138
62. Albert N.M. Manipulating survival and life quality outcomes in heart failure through disease state management. Crit Care Nurse Clin North Am. 11:1999;121-141
63. Graff L., Orledge J., Radford M., et al. Correlation of the Agency for Health Care Policy and Research Congestive Heart Failure Admission Guideline with Mortality Peer Review Organization Voluntary Hospital Association Initiative to Decrease Events (PROVIDE) for Congestive Heart Failure. Ann Emerg Med. 34:1999;429-437
64. Hammerer-Lercher A., Neubauer E., Muller S., et al. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta. 310:2001;193-197
65. Peacock W.F., Emerman C.L., Doleh M., et al. The incidence of elevated cardiac enzymes in decompensated heart failure. Acad Emerg Med. 5:2001;552
66. Arroliga A.C. Noninvasive positive pressure ventilation in acute respiratory failure Does it improve outcomes? Cleve Clin J Med. 68:2001;677-802
67. Peacock W.F. 4th, Albert N.M. Observation unit management of heart failure. Emerg Med Clin North Am. 19:2001;209-232
68. Vinson J.M., Rich M.W., Sperry J.C., et al. Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc. 38:1990;1290-1295
69. Rich M.W., Beckham V., Wittenberg C., et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 333:1995;1190-1195
70. Rich M.W., Vinson J.M., Sperry J.C., et al. Prevention of readmission in elderly patients with congestive heart failure. J Gen Intern Med. 8:1993;585-590
71. Peacock W., Aponte J., Craig M., et al. Predictors of unsuccessful treatment for congestive heart failure in the emergency department observation unit. Acad Emerg Med. 4:1997;494
72. Albert N.M., Peacock W.F. Patient outcome and costs after implementation of an acute heart failure management program in an emergency department observation unit. J Int Soc Heart Lung Transplant. 18:1999;92
73. Peacock W.F., Aponte J.H., Craig M.T., et al. Inpatient versus emergency department observation unit management of heart failure. Ann Emerg Med. 32:1998;S46
74. Cline C.M.J., Israelsson B.Y.A., Willenheimer R.B., et al. Cost effective management program for heart failure reduces hospitalization. Heart. 80:1998;442-446
75. Fonarow G.C., Stevenson L.W., Walden J.A., et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol. 30:1997;725-732
76. Gattis W., Hasselblad V., Whellan D., et al. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team. Arch Intern Med. 159:1999;1939-1945
77. Quaglietti S.E., Atwood J.E., Ackerman L., et al. Management of the patient with congestive heart failure using outpatient, home, and palliative care. Prog Cardiovasc Dis. 43:2000;259-274
78. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enlapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 325:1991;303-310
79. Cohn J.N., Archibald D.G., Ziesche S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure Results of the Veterans Administration Cooperative Study. N Engl J Med. 314:1986;1547-1552
80. The SOLVD Investigators. Effect of enlapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302
81. The CONSENSUS Trial Study Group. Effects of enlapril on mortality in severe congestive heart failure Results of the Cooperative North Scandinavian Enlapril Survival Study (CONSENSUS). N Engl J Med. 315:1987;1429-1435
82. Marcus L.S., Hart D., Packer M., et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation. 94:1996;3184-3189
83. Abraham W.T., Lowes B.D., Ferguson D.A., et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 4:1998;37-44
84. Burger A.J., Horton D.P., Elkayam U., et al. Nesiritide is not associated with the proarrhythmic effects of dobutamine in the treatment of decompensated CHF The PRECEDENT Study. J Cardiac Failure. 5:(Suppl 1):1999;178
85. Elkayam U., Silver M.A., Burger A.J., et al. The effect of short-term therapy with nesiritide (B-type natriuretic peptide) or dobutamine on long-term survival. J Cardiac Failure. 6:(Suppl 2):2000;169
86. Young J.B., Stevenson L.W., Abraham W.T., et al. Rationale and design of the VMAC Trial Vasodilation in the Management of Acute Congestive Heart Failure. J Cardiac Failure. 6:(Suppl 2):2000;182
87. Zellner C., Protter A.A., Ko E., et al. Coronary vasodilator effects of BNP Mechanisms of action in coronary conductance and resistance arteries. Am J Physiol. 276:1999;H1049-1057
88. Colucci W.S., Elkayam U., Horton D.P., et al. Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 343:2000;246-253
89. Silver M.A., Ghali J.K., Horton D.P., et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of acutely decompensated heart failure. J Cardiac Failure. 4:(Suppl 1):1998;150A
90. Peacock W.F., Emerman C.E., Young J. PROACTION study group. Safety and efficacy of nesiritide for the treatment of decompensated heart failure in emergency department observation unit patients. J Am Coll Cardiol. 4:(Suppl A):2003;336A
91. Colucci W.S., Packer M., Bristow M.R., et al. US Carvedilol Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 94:1996;2800-2806
92. Tsuyuki R.T., Yusuf S., Rouleau J.L., et al. Combination neurohormonal blockade with ACE inhibitors, angiotensin II, antagonists and beta-blockers in patients with congestive heart failure Design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVED) pilot study (phase II). Eur Heart J. 19S:1998;308. abstract
93. The International Steering Committee. Rationale, design, and organization of the Metoprolol CR/XL randomized intervention trial in heart failure (MERIT-HF). Am J Cardiol. 80:(Suppl 9B):1997;54J-58J
94. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 90:1994;1765-1773
95. Bristow M.R., Gilbert E.M., Abraham W.T., et al. MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 94:1996;2807-2816
96. Cioffi G., Pozzoli M., Forni G., et al. Systemic thromboembolism in chronic heart failure. A prospective study in 406 patients. Eur Heart J. 17:1996;1381-1389
97. Baker D.W., Wright R.F. Management of heart failure. IV. Anticoagulation for patients with heart failure due to left ventricular systolic dysfunction. JAMA. 272:1994;1614-1618
98. ACC/AHA. Guidelines for the evaluation and management of heart failure Report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee of Evaluation and Management of Heart Failure). Circulation. 92:1995;2764-2784
99. Turpie A.G. Thrombosis prophylaxis in the acutely ill medical patient insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. Am J Cardiol. 86:(12B):2000;48M-52M
100. Elkayam U., Weber L., McKay C., et al. Spectrum of acute hemodynamic effects of nifedipine in severe congestive heart failure. Am J Cardiol. 56:1985;560-566
101. Barjon J.N., Rouleau J.L., Bichet D., et al. Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure. J Am Coll Cardiol. 9:1987;622-630
102. Elkayam U., Amin J., Mehra A., et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 82:1990;1954-1961
103. Goldstein R.E., Boccuzzi S.J., Cruess D., et al. The Adverse Experience Committee and the Multicenter Diltiazem Post-infarction Research Group. Diltiazem increase late-onset congestive heart failure in post-infarction patients with early reduction in ejection fraction. Circulation. 83:1991;52-60
104. The Cardiac Arrhythmia Suppression Trail (CAST) Investigators. Preliminary report Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 321:1989;406-412
105. Doval H.C., Nul D.R., Grancelli H.O., et al. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet. 344:1994;493-498
106. Singh S.N., Fletcher R.D., Fisher S.G., et al. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmias. N Engl J Med. 333:1995;77-82
107. Grossman W. Diastolic dysfunction in congestive heart failure. N Engl J Med. 325:1991;1557-1564